RAFAELE CALAMIA: Open Payments
NPI 1134295173 · BRYN MAWR, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,346 in 87 payments from 18 companies in 2025. Trend: 2023 $1,379 · 2024 $1,668 · 2025 $1,346
Food & beverage: $1,333Education: $13
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $295 |
| ABBVIE INC. | 28 | $216 |
| Amgen Inc. | 12 | $152 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 8 | $151 |
| GENZYME CORPORATION | 3 | $97 |
| UCB, Inc. | 2 | $62 |
| LEO Pharma Inc. | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Incyte Corporation | 2 | $52 |
| E.R. Squibb & Sons, L.L.C. | 2 | $42 |
Products named: TREMFYA, SKYRIZI, OTEZLA, DUPIXENT, ILUMYA, Bimzelx, OPZELURA, Winlevi.
Industry payments across PA — which companies pay providers there.
